Literature DB >> 20363541

KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).

Katrin Uhlig1, Jeffrey S Berns, Bryan Kestenbaum, Raj Kumar, Mary B Leonard, Kevin J Martin, Stuart M Sprague, Stanley Goldfarb.   

Abstract

This commentary provides a US perspective on the 2009 KDIGO (Kidney Disease: Improving Global Outcomes) Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). KDIGO is an independent international organization with the primary mission of the promotion, coordination, collaboration, and integration of initiatives to develop and implement clinical practice guidelines for the care of patients with kidney disease. The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI), recognizing that international guidelines need to be adapted for each country, convened a group of experts to comment on the application and implementation of the KDIGO guideline for patients with CKD in the United States. This commentary puts the KDIGO guideline into the context of the supporting evidence and the setting of care delivered in the United States and summarizes important differences between prior KDOQI guidelines and the newer KDIGO guideline. It also considers the potential impact of a new bundled payment system for dialysis clinics. The KDIGO guideline addresses the evaluation and treatment of abnormalities of CKD-MBD in adults and children with CKD stages 3-5 on long-term dialysis therapy or with a kidney transplant. Tests considered are those that relate to laboratory, bone, and cardiovascular abnormality detection and monitoring. Treatments considered are interventions to treat hyperphosphatemia, hyperparathyroidism, and bone disease in patients with CKD stages 3-5D and 1-5T. Limitations of the evidence are discussed. The lack of definitive clinical outcome trials explains why most recommendations are not of level 1 but of level 2 strength, which means weak or discretionary recommendations. Suggestions for future research highlight priority areas. Copyright 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20363541     DOI: 10.1053/j.ajkd.2010.02.340

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  78 in total

1.  The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.

Authors:  Dan Li; Leping Shao; Haiyan Zhou; Wei Jiang; Wei Zhang; Yan Xu
Journal:  Endocrine       Date:  2012-06-06       Impact factor: 3.633

2.  Effects of frequent hemodialysis on measures of CKD mineral and bone disorder.

Authors:  John T Daugirdas; Glenn M Chertow; Brett Larive; Andreas Pierratos; Tom Greene; Juan Carlos Ayus; Cynthia A Kendrick; Sam H James; Brent W Miller; Gerald Schulman; Isidro B Salusky; Alan S Kliger
Journal:  J Am Soc Nephrol       Date:  2012-02-23       Impact factor: 10.121

3.  Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients.

Authors:  Jessica E Miller; Csaba P Kovesdy; Keith C Norris; Rajnish Mehrotra; Allen R Nissenson; Joel D Kopple; Kamyar Kalantar-Zadeh
Journal:  Am J Nephrol       Date:  2010-09-03       Impact factor: 3.754

4.  New clinical trials with vitamin D and analogs in renal disease.

Authors:  Rajiv Kumar
Journal:  Kidney Int       Date:  2011-08-10       Impact factor: 10.612

5.  CKD-mineral and bone disorder: core curriculum 2011.

Authors:  Ranjani N Moorthi; Sharon M Moe
Journal:  Am J Kidney Dis       Date:  2011-10-21       Impact factor: 8.860

6.  Dysphoria induced in dialysis providers by secondary hyperparathyroidism.

Authors:  Irfana H Soomro; David S Goldfarb
Journal:  Clin J Am Soc Nephrol       Date:  2014-12-16       Impact factor: 8.237

7.  Vascular calcification in predialysis CKD: common and deadly.

Authors:  Wei Chen; Michal L Melamed
Journal:  Clin J Am Soc Nephrol       Date:  2015-03-13       Impact factor: 8.237

8.  Long-Term Parathyroid Hormone 1-34 Replacement Therapy in Children with Hypoparathyroidism.

Authors:  Karen K Winer; Andrea Kelly; Alicia Johns; Bo Zhang; Karen Dowdy; Lauren Kim; James C Reynolds; Paul S Albert; Gordon B Cutler
Journal:  J Pediatr       Date:  2018-12       Impact factor: 4.406

9.  Deoxycholic Acid, a Metabolite of Circulating Bile Acids, and Coronary Artery Vascular Calcification in CKD.

Authors:  Anna Jovanovich; Tamara Isakova; Geoffrey Block; Jason Stubbs; Gerard Smits; Michel Chonchol; Makoto Miyazaki
Journal:  Am J Kidney Dis       Date:  2017-08-09       Impact factor: 8.860

10.  Management of mineral metabolism in hemodialysis patients: discrepancy between interventions and perceived causes of failure.

Authors:  Pasquale Esposito; Teresa Rampino; Marilena Gregorini; Carmine Tinelli; Annalisa De Silvestri; Fabio Malberti; Rosanna Coppo; Antonio Dal Canton
Journal:  J Nephrol       Date:  2014-05-08       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.